Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Drug Safety Office Reorganizing To Accommodate Influx Of PDUFA Staff

Executive Summary

FDA's Office of Surveillance and Epidemiology is again undergoing changes as the agency continues to strengthen its drug safety operations. OSE is reorganizing prior to increasing staff by 50 percent to undertake new regulatory authorities
Advertisement

Related Content

Chart: Avoiding Name Confusion At OSE
FDA Drug Review, Surveillance Offices Agree To Share Safety Authority
FDA Drug Review, Surveillance Offices Agree To Share Safety Authority
FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing
FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing
Safety First: FDA Unveils New Postmarketing Management Process For Safety
FDAAA Cornucopia: REMS To Be Used Sparingly; Trial Database On Schedule
FDA Putting System In Place For RiskMAP Evaluation And Management
Rx Safety Gets More Attention From CERTs With Addition Of Health IT Center
FDA’s Drug Center Reorganization Creates Second Safety Director Position
Advertisement
UsernamePublicRestriction

Register

PS049336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel